Pancreatic cancer therapies remain limited in scope and patient prognoses remain poor. To effectively improve pancreatic cancer outcomes, a highly targeted therapeutic is necessary. A bioconjugated gold nanoparticle (AuNP) provides such a therapeutic platform. Effective targeting of the nanoparticle is possible through the linkage of antibodies to target key antigens highly expressed on the sur...

ß6-integrin immunohistochemistry analysis of a large number of pancreatic ductal adenocarcinoma (PDAC, 383 primary tumors, 7 lymph node, and 8 distant metastases) and 34 pancreatic intraepithelial neoplasia (PanIN) specimens revealed a high prevalence of αvß6-integrin expression in PDAC primaries (88%) and in almost all metastases, as well as in PanIN (57%). These findings underscore the high p...

Pancreatic ductal adenocarcinoma (PDAC) is characterized by an extensive fibrotic reaction or desmoplasia and complex involvement of the surrounding tumor microenvironment. Pancreatic stellate cells are a key mediator of the pancreatic matrix and they promote progression and invasion of pancreatic cancer by increasing cell proliferation and offering protection against therapeutic interventions....

Objective(s):The purpose of this study was to investigate the effects of Noggin on high glucose-induced apoptosis and insulin secretion in pancreatic beta cells. Materials and Methods: Different concentrations of glucose were used to examine their effects on INS-1 rat beta cells in vitro. When specific siRNA targeting Noggin and recombinant Noggin were added, apoptosis and insulin secretion wer...

primary pancreatic lymphoma is a rare extranodal manifestation of any histopathologic subtype of b cell non-hodgkin's lymphoma that predominantly involves the pancreas. it comprises less than 0.2% of pancreatic malignancies and less than 0.7% of non-hodgkin's lymphomas. this lymphoma is almost never suspected clinically. it is usually diagnosed by surgical exploration for suspected ad...

Promotiecommissie Promotoren: Chapter 1 General Introduction: Improvement strategies for peptide receptor scintigraphy and radionuclide therapy. 7 Part I Neurotensin analogs for in vivo targeting of exocrine pancreatic cancer Chapter 2 Stabilised 111 In-labeled DTPA-and DOTA-conjugated neurotensin analogs for imaging and therapy of exocrine pancreatic cancer. 43 Chapter 3 Five stabilized 111 In...

The aim of this study was to construct a lentivirus vector targeting RhoT1 gene and to investigate the functional role of RhoT1 in pancreatic cancer cell line BXPC3. Firstly, we constructed a lentivirus plasmid of RNA interference targeting RhoT1. The expression of RhoT1 mRNA and protein was analyzed by qRT-PCR and Western blot. The CCK-8 cell proliferation assay, flow cytometry, wound healing ...

PURPOSE OF REVIEW The recent advances in the use of targeted therapy in pancreatic cancer are based on the knowledge of genetic alterations that occur during pancreatic carcinogenesis. We describe the repository of frequent alterations targeting tumour suppressor genes and oncogenes. We focus our attention on the epidermal growth factor receptor signalling pathway, which can be activated throug...

Pancreatic cancer-associated stellate cells secrete soluble factors, such as interleukin-6 (IL-6), that promote the accumulation of myeloid-derived suppressor cells via a signal transducer and activator of transcription 3 (STAT3)-dependent mechanism. Targeting components of the IL-6/JAK/STAT3 signaling axis within the tumor stroma could therefore inhibit local immunosuppression and improve the ...

Pancreatic cancer is relatively insensitive to conventional chemotherapy. Therefore, novel agents targeting dysregulated pathways (MAPK/ERK, EGFR, TGF-β, HEDGEHOG, NOTCH, IGF, PARP, PI3K/AKT, RAS, and Src) are being explored in clinical trials as monotherapy or in combination with cytotoxic chemotherapy. This review summarizes the most recent advances with the targeted therapies in the treatmen...